Sorafenib






2844 Article(s)
Download
PMID
Title
Journal
Pub. Date
#Total Relationship(s)
1 11566613 Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001 Sep 2
2 12369852 BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des 2002 1
3 12369853 BAY 43-9006: preclinical data. Curr Pharm Des 2002 2
4 12503816 ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006. Int J Clin Pharmacol Ther 2002 Dec 1
5 14763129 Raf pathway inhibitors in oncology. Curr Opin Investig Drugs 2003 Dec 1
6 15035987 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004 Mar 19 2
7 15171791 Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. BMC Cancer 2004 Jun 1 1
8 15208680 B-RAF is a therapeutic target in melanoma. Oncogene 2004 Aug 19 4
9 15282098 Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum. J Chromatogr B Analyt Technol Biomed Life Sci 2004 Sep 25 2
10 15448036 Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004 Sep 15 9
11 15466206 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004 Oct 1 21
12 15598034 Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006. Int J Clin Pharmacol Ther 2004 Nov 1
13 15613696 Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005 Feb 10 1
14 15655409 The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 2005 Feb 6
15 15665559 Raf kinase inhibitors in oncology. Onkologie 2005 Feb 1
16 15781657 Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005 Mar 15 1
17 15819587 Improving outcomes in advanced malignant melanoma: update on systemic therapy. Drugs 2005 2
18 15850570 Peroxynitrite activates ERK via Raf-1 and MEK, independently from EGF receptor and p21Ras in H9C2 cardiomyocytes. J Mol Cell Cardiol 2005 May 6
19 15870716 Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005 May 23 2
20 16006586 Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005 Oct 1
21 16007148 The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005 Oct 20 11
22 16109713 Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005 Oct 21 9
23 16133532 Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006 May 13
24 16240452 Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 2005 Dec 1 6
25 16255777 Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med 2005 Oct 28 6
26 16405965 Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication. FEBS Lett 2006 Jan 23 3
27 16425993 Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer 2005 Dec 6
28 16446323 Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006 Mar 20 4
29 16452220 The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 2006 Feb 1 10
30 16474853 Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 2005 Dec 8
31 16498671 Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 2006 May 6
32 16503817 Sorafenib. Expert Opin Pharmacother 2006 Mar 2
33 16507829 BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006 Mar 1 5
34 16533790 BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006 Mar 1 1
35 16600618 Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). Crit Rev Oncol Hematol 2006 Jul 1
36 16640800 Emerging antiangiogenic agents in lung cancer. Clin Lung Cancer 2006 Mar 1
37 16645167 Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006 Aug 15 8
38 16685460 Comparative integromics on VEGF family members. Int J Oncol 2006 Jun 2
39 16702946 Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants. Oncogene 2006 Oct 26 1
40 16724239 Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 2007 Feb 3
41 16729906 Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma. Clin Genitourin Cancer 2006 Mar 1
42 16757355 Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006 18
43 16760274 Targeting Raf-kinase: molecular rationales and translational issues. Ann Oncol 2006 Jun 2
44 16824050 Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 2006 Nov 4
45 16850127 Molecular targeting therapy for renal cell carcinoma. Int J Clin Oncol 2006 Jun 6
46 16859583 Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports. Clin Genitourin Cancer 2006 Jun 2
47 16860997 Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol 2006 Dec 1
48 16869784 Cancer targets in the Ras pathway. Cold Spring Harb Symp Quant Biol 2005 2
49 16890795 Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006 Aug 9
50 16894562 Raf kinases: oncogenesis and drug discovery. Int J Cancer 2006 Nov 15 2